Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere Stock Offering Nets $27.7M

NEW YORK (GenomeWeb News) – Nanosphere has closed a public offering of common stock that has raised net proceeds of around $27.7 million.

The Northbrook, Ill.-based molecular diagnostics firm launched the offering last week. It sold 17,250,000 common shares at $1.75 per share, including 2,250,000 shares that made up the over-allotment option, which was exercised by the underwriters in full.

Nanosphere said that it will use the proceeds for general corporate purposes and working capital.

The company ended the second quarter with $32 million in cash and cash equivalents. In May it raised $4.7 million in net proceeds from a direct offering of its stock.

In Wednesday afternoon trade on the Nasdaq, shares of Nanosphere were down 2 percent at $1.87.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.